Global SPECT Radiopharmaceuticals Market Growth (Status and Outlook) 2025-2031

The global SPECT Radiopharmaceuticals market size is predicted to grow from US$ 5825 million in 2025 to US$ 15190 million in 2031; it is expected to grow at a CAGR of 17.3% from 2025 to 2031.

SPECT (Single Photon Emission Computed Tomography) radiopharmaceuticals are compounds that contain a radioactive isotope used in conjunction with SPECT imaging techniques. These radiopharmaceuticals emit gamma radiation, which is detected by a gamma camera during a SPECT scan, creating detailed 3D images of the internal structures and functions of the body. These radiopharmaceuticals are primarily used for diagnostic imaging, allowing healthcare providers to evaluate the function of organs, tissues, and systems without invasive procedures.

SPECT radiopharmaceuticals are a type of radioactive tracers used in nuclear medicine imaging that can help doctors detect heart disease, neurological diseases, cancer, bone diseases, and thyroid diseases. They rely on short-half-life radioisotopes to obtain physiological function information through SPECT scanners, and have important applications in modern medicine.

From a regional perspective, North America and Europe have advanced medical infrastructure and strong R&D capabilities. As the world's largest radiopharmaceutical market, they have promoted the widespread use of SPECT radiopharmaceuticals. The increase in medical demand in emerging markets such as Asia Pacific and Latin America will provide new growth momentum for the SPECT radiopharmaceutical market.

Global leading suppliers include GE Healthcare, Cardinal Health, Lantheus Medical Imaging, Bracco Imaging, Curium Pharma, etc. The production of radiopharmaceuticals requires complex nuclear technology and strict safety supervision. These high technical barriers limit the entry of new companies and maintain the stability of the market.

With the advancement of medical technology, new radioisotopes and labeling methods will be developed to improve the accuracy and efficiency of SPECT imaging and promote market development.

LPI (LP Information)' newest research report, the “SPECT Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world SPECT Radiopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected SPECT Radiopharmaceuticals sales for 2025 through 2031. With SPECT Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world SPECT Radiopharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global SPECT Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on SPECT Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global SPECT Radiopharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for SPECT Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global SPECT Radiopharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of SPECT Radiopharmaceuticals market by product type, application, key players and key regions and countries.

Segmentation by Type:
Technetium-99m (Tc-99m) Based Agents
Iodine-123 (I-123) Based Agents
Gallium-67 (Ga-67)
Indium-111 (In-111) Based Agents
Thallium-201 (Tl-201)

Segmentation by Application:
Cardiac Imaging
Cancer Imaging
Brain Imaging
Thyroid Imaging
Infection and Inflammation Imaging

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GE Healthcare
Cardinal Health
Lantheus Medical Imaging
Bracco Imaging
Curium Pharma
Eczacibasi-Monrol
Siemens Healthineers
Bayer (Radiology Division)
Molecular Imaging, Inc.
NorthStar Medical Radioisotopes
Advanced Accelerator Applications
IBA Molecular Imaging

Please note: The report will take approximately 2 business days to prepare and deliver.